EUVIMEDEUVIMED entdecken
Systematische Übersicht

Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review

Craig Witt iD, Lee G Renfroe, T Scott Lyons

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16335 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Craig Witt und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kinesiology, University of North Alabama, Florence, Alabama, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Lipoproteins, Metabolic Syndrome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review examines the discordance between low‐density lipoprotein cholesterol (LDL‐C), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), and apolipoprotein B‐100 (apoB) in individuals with metabolic diseases, such as metabolic syndrome and type 2 diabetes, and evaluates the implications for atherosclerotic cardiovascular disease (ASCVD) risk assessment. A systematic literature search was conducted using Academic Search Complete, CINAHL Complete, and MEDLINE databases from 10 January 2024 to 28 May 2024. Studies were selected based on pre‐defined inclusion and exclusion criteria, focusing on observational studies that compared LDL‐C, non‐HDL‐C, and apoB levels in individuals with metabolic disease. Studies were included if they assessed fasted blood samples and reported lipid measurements, excluding those involving drug therapies or dietary interventions. Nine studies met the inclusion criteria, revealing significant discordance between LDL‐C and apoB levels in individuals with metabolic syndrome or type 2 diabetes. These individuals often achieve optimal LDL‐C levels while exhibiting elevated apoB and non‐HDL‐C concentrations, highlighting the limitations of LDL‐C as the sole marker for ASCVD risk. The discordance is largely attributed to differences in LDL particle size and density, with metabolic disease contributing to a higher proportion of small, dense, atherogenic LDL particles. Elevated triglyceride‐rich lipoproteins (TRLs), such as very low‐density lipoproteins (VLDL), were also identified as contributing to ASCVD risk underestimation by traditional LDL‐C measurements. While LDL‐C remains a central marker for ASCVD, apoB quantification provides a more accurate assessment of ASCVD risk, particularly in individuals with metabolic diseases. Incorporating apoB levels into therapeutic strategies for lipid reduction is recommended to improve cardiovascular risk management in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisLipoproteinsMetabolic SyndromeDiabetes Mellitus, Type 2Cholesterol, LDLCholesterolMetabolic DiseasesHumansApolipoprotein B-100Biomarkers

Stichwörter der Autor:innen

apolipoprotein B‐100atherosclerotic cardiovascular diseaselow‐density lipoprotein cholesterolmetabolic syndromenon‐high‐density lipoprotein cholesteroltype 2 diabetes

Substanzen

LipoproteinsCholesterol, LDLApolipoprotein B-100CholesterolBiomarkers

Autor:innen und Institutionen

  • Department of Kinesiology, University of North Alabama, Florence, Alabama, USA.

ORCID-Profile: Craig Witt

Zitieren

APA

Witt, C., Renfroe, L. G., & Lyons, T. S. (2025). Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16335

Vancouver

Witt C, Renfroe LG, Lyons TS. Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16335

BibTeX
@article{Witt2025,
  author = {Witt, Craig and Renfroe, Lee G and Lyons, T Scott},
  title = {Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16335}
}
Kostenlos starten →